Xencor terminates deal granting Amgen an option to license exclusive, worldwide rights to autoimmune candidate Xmab5871

Xencor Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Amgen Inc.

U.S. / Large-Cap Biopharma (>=$50 billion)

$51,870.4m on 12/31/2010 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Terminated

Sample

01/01/2009

announced

01/01/2009

Terminated